180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 78.8% in September

180 Life Sciences Corp. (NASDAQ:ATNF) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 60,600 shares, a growth of 78.8% from the August 31st total of 33,900 shares. Currently, 11.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 566,000 shares, the short-interest ratio is currently 0.1 days.

180 Life Sciences Trading Down 4.0 %

ATNF stock traded down $0.07 during trading on Friday, hitting $1.68. The company had a trading volume of 33,466 shares, compared to its average volume of 277,166. The company has a 50 day simple moving average of $1.94 and a 200-day simple moving average of $2.00. 180 Life Sciences has a 52-week low of $1.31 and a 52-week high of $12.02.

180 Life Sciences (NASDAQ:ATNF) last posted its quarterly earnings results on Monday, August 12th. The company reported $0.01 earnings per share (EPS) for the quarter.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.